-
Je něco špatně v tomto záznamu ?
Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest
B. Vítovcová, V. Skarková, R. Havelek, J. Soukup, A. Pande, K. Caltová, E. Rudolf
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-12-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
Springer Nature OA/Free Journals
od 2011-12-01
- MeSH
- apoptóza MeSH
- buněčný cyklus MeSH
- dospělí MeSH
- glioblastom * patologie MeSH
- kontrolní body buněčného cyklu MeSH
- lidé MeSH
- mebendazol farmakologie terapeutické užití MeSH
- nádorové buněčné linie MeSH
- nádory mozku * patologie MeSH
- proliferace buněk MeSH
- transkripční faktor STAT3 metabolismus MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Glioblastoma multiforme (GBM) belongs to most aggressive and invasive primary brain tumor in adults whose prognosis and survival remains poor. Potential new treatment modalities include targeting the cytoskeleton. In our study, we demonstrated that repurposed drug flubendazole (FLU) significantly inhibits proliferation and survival of GBM cells. FLU exerted its effect by affecting microtubule structure and our results also suggest that FLU influences tubulins expression to a certain degree. Moreover, FLU effects decreased activation of STAT3 and also partially inhibited its expression, leading to upregulation of p53 signaling pathway and subsequent cell cycle arrest at G2/M phase as well as caspase-dependent cell death in GBM cells. These results suggest FLU as a promising agent to be used in GBM treatment and prompting further testing of its effects on GBM.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010450
- 003
- CZ-PrNML
- 005
- 20230801132432.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-023-33047-9 $2 doi
- 035 __
- $a (PubMed)37045903
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vítovcová, Barbora $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic. vitovcob@lfhk.cuni.cz
- 245 10
- $a Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest / $c B. Vítovcová, V. Skarková, R. Havelek, J. Soukup, A. Pande, K. Caltová, E. Rudolf
- 520 9_
- $a Glioblastoma multiforme (GBM) belongs to most aggressive and invasive primary brain tumor in adults whose prognosis and survival remains poor. Potential new treatment modalities include targeting the cytoskeleton. In our study, we demonstrated that repurposed drug flubendazole (FLU) significantly inhibits proliferation and survival of GBM cells. FLU exerted its effect by affecting microtubule structure and our results also suggest that FLU influences tubulins expression to a certain degree. Moreover, FLU effects decreased activation of STAT3 and also partially inhibited its expression, leading to upregulation of p53 signaling pathway and subsequent cell cycle arrest at G2/M phase as well as caspase-dependent cell death in GBM cells. These results suggest FLU as a promising agent to be used in GBM treatment and prompting further testing of its effects on GBM.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a glioblastom $x patologie $7 D005909
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a kontrolní body buněčného cyklu $7 D059447
- 650 _2
- $a mebendazol $x farmakologie $x terapeutické užití $7 D008463
- 650 _2
- $a proliferace buněk $7 D049109
- 650 12
- $a nádory mozku $x patologie $7 D001932
- 650 _2
- $a apoptóza $7 D017209
- 650 _2
- $a buněčný cyklus $7 D002453
- 650 _2
- $a transkripční faktor STAT3 $x metabolismus $7 D050796
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Skarková, Veronika $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic
- 700 1_
- $a Havelek, Radim $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic
- 700 1_
- $a Soukup, Jiří $u The Fingerland Department of Pathology, Faculty of Medicine and University Hospital in Hradec Králové, Charles University, Sokolská 581, 500 05, Hradec Králové, Czech Republic
- 700 1_
- $a Pande, Ananya $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic
- 700 1_
- $a Caltová, Kateřina $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic
- 700 1_
- $a Rudolf, Emil $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 13, č. 1 (2023), s. 5993
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37045903 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132429 $b ABA008
- 999 __
- $a ok $b bmc $g 1963084 $s 1196715
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 13 $c 1 $d 5993 $e 20230412 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- LZP __
- $a Pubmed-20230718
